Mdm2 promotes the rapid degradation of p53

Nature

Volumn 387, Issue 6630, 1997, Pages 296-299

  Haupt, Ygal ^a   Maya, Ruth ^b   Kazaz, Anat ^b   Oren, Moshe ^b  

^a HEBREW UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CELL PROLIFERATION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; DOWN-REGULATION; HELA CELLS; HUMANS; MICE; NUCLEAR PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030905284     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/387296a0     Document Type: Article

References (29)

1. Gottlieb, T. & Oren, M. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287, 77-102 (1996).
2. Shen, Y. & Shenk, T. E. Viruses and apoptosis. Curr. Opin. Gene. Dev. 5, 105-111 (1995).
3. Picksley, S. M. & Lane, D. P. The p53-mdm2 autoregulatory feedback loop - a paradigm for the regulation of growth control by p53? Bioessays 15, 689-690 (1993).
4. Chen, J. D., Lin, J. Y. & Levine, A. J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med. 1, 141-142 (1995).
5. Chen, C. Y. et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl Acad. Sc. USA 91, 2684-2688 (1994).
6. Haupt, Y., Barak, Y. & Oren, M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15, 1596-1606 (1996).
7. Chen, J. D., Wu, X., Lin, J. Y. & Levine, A. J. mdm-2 inhibitis the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16, 2445-2452 (1996).
8. Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D. & Levine, A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl Acad. Sci. USA 90, 11623-11627 (1993).
9. Barak, Y., Gottlieb, E., Juven-Gershon, T. & Oren, M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8, 1739-1749 (1994).
10. Lin, J. Y., Chen, J. D., Elenbaas, B. & Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246 (1994).
11. Hinds, P. W. et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells - a comparison of the hot spot mutant phenotype. Cell Growth Diff. 1, 571-580 (1990).
12. Unger, T., Nau, M. M., Segal, S. & Minna, J. D. p53 - a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11, 1383-1390 (1992).
13. Oren, M., Reich, N. C. & Levine, A. J. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol. Cell. Biol. 2, 443-449 (1982).
14. Yonish-Rouach, E. et al. Induction of apoptosis by transiently transfected metabolically stable wt p53 is transformed cell lines. Cell Death Differ. 1, 39-47 (1994).
15. Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773-785 (1994).
16. Maki, C. J., Huibregtse, J. M. & Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56, 2649-2654 (1996).
17. Kubbutat, M. H. & Vousden, K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17, 460-468 (1997).
18. Gottlieb, E., Lindner, S. & Oren, M. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells. Cell Growth Diff. 7, 301-310 (1996).
19. Lane, D. P. The regulation of p53 function: Steiner award lecture. Int. J. Cancer 57, 623-627 (1994).
20. Bartek, J., Iggo, R., Gannon, J. & Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5, 893-899 (1990).
21. Martin, K. et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375, 691-694 (1995).
22. Xiao, Z. X. et al. Interaction between the retinoblastoma protein and the oncoprotein Mdm2. Nature 375, 694-698 (1995).
23. Momand, J. & Zambetti, G. P. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 12, 2279-2289 (1996).
24. Kastan, M. B., Onyekwere, O., Sindransky, D., Vogelstein, B. & Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
25. Fiscella, M. et al. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8, 1519-1528 (1993).
26. Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505 (1993).
27. Otto, A. & Deppert, W. Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene 8, 2591-2603 (1993).
28. Jones, S. N., Roe, A. E., Donehower, L. A. & Bradley, A. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 378, 206-208 (1995).
29. Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995).